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Abstract
Infectious disease treatments, both pharmaceutical and vaccine, face three universal challenges: the difficulty of targeting
treatments to high-risk ‘superspreader’ populations who drive the great majority of disease spread, behavioral barriers in
the host population (such as poor compliance and risk disinhibition), and the evolution of pathogen resistance. Here, we
describe a proposed intervention that would overcome these challenges by capitalizing upon Therapeutic Interfering
Particles (TIPs) that are engineered to replicate conditionally in the presence of the pathogen and spread between
individuals — analogous to ‘transmissible immunization’ that occurs with live-attenuated vaccines (but without the
potential for reversion to virulence). Building on analyses of HIV field data from sub-Saharan Africa, we construct a multi-
scale model, beginning at the single-cell level, to predict the effect of TIPs on individual patient viral loads and ultimately
population-level disease prevalence. Our results show that a TIP, engineered with properties based on a recent HIV gene-
therapy trial, could stably lower HIV/AIDS prevalence by ,30-fold within 50 years and could complement current therapies.
In contrast, optimistic antiretroviral therapy or vaccination campaigns alone could only lower HIV/AIDS prevalence by ,2-
fold over 50 years. The TIP’s efficacy arises from its exploitation of the same risk factors as the pathogen, allowing it to
autonomously penetrate superspreader populations, maintain efficacy despite behavioral disinhibition, and limit viral
resistance. While demonstrated here for HIV, the TIP concept could apply broadly to many viral infectious diseases and
would represent a new paradigm for disease control, away from pathogen eradication but toward robust disease
suppression.
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Introduction
From ‘core groups’ to ‘superspreaders’, epidemiologists have
long recognized the immense potential of targeting high-risk
groups for efficient control of infectious diseases [1,2,3,4]. These
groups are often described by the classic ‘80/20 rule’ [5] where
20% of the individuals drive 80% of disease transmission and thus
dominate the overall pattern of disease prevalence. For sexually
transmitted and blood-borne infections such as Hepatitis C [6],
syphilis [7], and HIV-1 [8,9] (here termed HIV), superspreading is
driven by high-risk sexual or needle-sharing behaviors. For many
other pathogens, spanning a broad range of transmission modes
and life histories, superspreading plays an important role in
transmission dynamics but the underlying mechanisms remain
poorly understood [4,10,11].
Targeting these superspreader subpopulations for therapeutic or
preventive measures would tremendously increase the efficacy of
disease control [3,4], while failure to target high-risk groups
weakens efforts to achieve ‘herd immunity’ by vaccination and
severely limits the ability to reduce disease at the population level
[12]. Unfortunately, identifying these crucial high-risk populations
requires in-depth knowledge of the social or sexual networks that
underlie disease spread, which is rarely attainable [13], as well as
knowledge of as-yet unknown biological correlates of risk. Further
aggravating the problem of targeting superspreaders are: (i) non-
healthseeking behaviors in the key populations, such as injection
drug users (IDUs); and (ii) self-concealment motivated by social
stigmas and criminal barriers in high-risk individuals, such as
IDUs, men who have sex with men, people with extra-marital
sexual partners, and commercial sex workers and their clients.
The resulting high cost and effort involved in identifying high-
risk populations has meant that—despite the huge potential
benefits—targeting of disease control measures to high-risk
populations is often not feasible in practice [14]. Here, we propose
a fundamentally different approach that obviates the need to
directly identify high-risk populations by engineering a therapeutic
version of interfering particles (i.e. TIPs) that spread between
individuals to autonomously target high-risk groups. The results
demonstrate the potential of TIPs to control HIV in sub-Saharan
Africa and we benchmark the performance of TIPs against the
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known to effectively reduce HIV incidence and prevalence, and a
hypothetical protective vaccine against HIV. We further demon-
strate that the effect of TIPs is complementary to ART programs,
so our proposed therapy could be rolled out synergistically with
current campaigns.
The concept: A proposal for transmissible gene therapies
The TIP concept capitalizes upon and extends the phenomenon
of interfering particles that occur naturally in many viruses, spread
along with the viral pathogen [15], and have demonstrated
potential therapeutic efficacy against HIV [16,17,18,19]. TIPs are
minimal versions of the pathogen engineered to lack the virulent
replication and structural genes of the wild-type pathogen and
instead encode therapeutic elements that target key host or viral
processes. Since a TIP genome is significantly shorter than the
wild-type virus genome, TIP genomes are synthesized at a faster
rate, resulting in increased numbers of TIP genomes compared to
wild-type virus genomes in the infected cell (see Text S1 and [15]).
Specifically, for HIV, the proposed TIP is a lentiviral gene-therapy
vector that lacks all structural and envelope genes required to self-
replicate, but retains HIV’s genomic packaging signals. The TIP
can mobilize out of the infected cell only by co-opting wild-type
HIV capsid and envelope gene-products [16]. By parasitizing a
pathogen’s resources, TIPs mobilize from cell to cell [16,18] and,
in a recent clinical trial, this mobilization of a gene-therapy vector
against HIV did not appear to be detrimental to patient health
[17]. Due to their ability to mobilize and reproduce within hosts,
TIPs have the potential to decrease wild-type pathogen levels in
vivo by many orders of magnitude [19].
By sharing all packaging elements with the wild-type pathogen,
TIPs also have the potential to spread between individuals [20],
and would spread via the same transmission routes as the disease-
causing pathogen. In this respect, combating an infectious disease
using TIPs raises unique safety and ethical concerns but bears
similarity to the use of live attenuated vaccines. In particular, a
recognized advantage of Oral Polio Vaccine (OPV) is that it
replicates in vivo and sheds, thereby transmitting among susceptible
hosts and delivering additional protection via ‘transmissible
immunization’ at the population scale [21]. There are, however,
crucial differences between TIPs and live attenuated vaccines: (i)
TIPs cannot replicate in uninfected hosts and, at most, the TIP
will remain dormant until the host is coinfected by wildtype
pathogen [22]; and (ii) replication elements are missing from the
TIP, so, unlike OPV, TIP cannot revert to virulence in healthy
individuals.
Results/Discussion
Projected impact of TIPs as HIV control measures
To test whether a TIP against HIV could autonomously target
high-risk groups, and effectively reduce HIV prevalence, we build
upon an established epidemiological model of HIV/AIDS
transmission in sub-Saharan Africa that includes four classes of
sexual risk behavior based on field data [12]. We develop a data-
driven, three-scale model (Figure 1) that translates molecular-level
characteristics of the TIP to predict patient-level HIV viral load
and ultimately predict HIV/AIDS incidence and prevalence at the
population scale. At the single-cell level, the model considers the
dynamics of competition between TIP genomic mRNA and HIV
genomic mRNA for packaging components [23]. These molecu-
lar-level effects of the TIP are translated to viral loads using an
established in vivo model of HIV dynamics [24] that includes TIP
dynamics [19]. Measured relationships between viral load and
transmission [25] are used to estimate TIP and HIV transmission
rates between individuals, and the rate of disease progression is
estimated based on field data of HIV viral load [26] (see Text S1).
For ART, the model assumes an optimistic ‘test-and-treat’
deployment [27] where 75% of all infections in both high-risk and
low-risk populations are treated with regimens that stop 99% of all
HIV transmission [27]. Our test-and-treat model differs from
some previous projections [27,28] by incorporating two additional
behavioral factors described in real populations [29]: (i) ART
failure or dropout rates that have been measured in sub-Saharan
African populations [30,31,32]; (ii) population risk structure.
While our model predicts smaller benefits from test-and-treat
programs than some earlier work [27,28], the results are consistent
with previous ART projections that have incorporated risk
structure [12,33].
For the vaccine, the model assumes optimistic immunization
coverage (80% or 95% coverage) of both high-risk and low-risk
populations and considers a vaccine that is 30% protective, slightly
higher than reported in the recent ‘Thai trial’ [34], or a
hypothetical 50% protective vaccine; life-long efficacy is assumed
for both vaccines (i.e. no HIV mutational escape) but not for the
TIP. For the TIPs, we analyze interventions that generate a 0.5-
Log to 1.5-Log viral-load reduction in vivo, as reported in a recent
HIV gene-therapy trial [17]. The model predicts the effects of
vaccination or TIP intervention on HIV/AIDS prevalence in a
resource-poor sub-Saharan setting.
Strikingly, TIP intervention reduces disease prevalence and
incidence more effectively than either widespread ART or a 30%
or 50% protective vaccine against HIV/AIDS (Figure 2a–b). The
least effective TIP analyzed—which reduces HIV in vivo viral load
by 0.5-Log (from 10
5 to 10
4.5 copies/mL)—leads to a reduction in
HIV/AIDS prevalence from 29% to 6.5% in 50 years, despite
initial deployment to only 1% of individuals while a TIP that
generates a 1.5-Log decrease in HIV viral-load—as transiently
achieved in a Phase-I clinical trial for an HIV gene-therapy [17]—
would reduce HIV/AIDS prevalence from 29% to below 1%
prevalence in 30 years (Figure 2a). In comparison, a 30%
Author Summary
We introduce a proposed intervention against infectious
diseases that extends and optimizes the recognized
benefit of ‘transmissible immunization’ that occurs with
live-attenuated vaccines such as Oral Polio Vaccine (OPV),
the vaccine chosen for the worldwide polio eradication
campaign. The intervention proposed here is based upon
Therapeutic Interfering Particles (TIPs) that are engineered
to replicate only in the presence of the wildtype pathogen
and act to inhibit the growth of the pathogen. Therefore
TIPs ‘piggyback’ on the pathogen, leading to two
important differences from live-attenuated vaccines: TIPs
can only transmit from individuals already infected with
wildtype pathogen, and TIPs could only revert to virulence
in individuals already carrying the wild-type pathogen.
Intriguingly, because TIPs spread between individuals
using the same transmission routes as the pathogen, they
automatically find their way to the populations at greatest
risk of infection, thus circumventing the unsolved problem
of how to identify superspreaders and target them for
preventive measures. Based on clinical-trial data, we
analyze the impact that TIP intervention would have on
HIV/AIDS in sub-Saharan Africa and show that TIPs could
lower HIV/AIDS prevalence more effectively than vaccines
or drugs alone and, in fact, would effectively complement
these other interventions.
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(including 8 out of 10 uninfected high-risk individuals) reduces
HIV/AIDS prevalence from 29% to 23.9% in 50 years and a 50%
protective vaccine deployed to 95% of the entire population
(including virtually all uninfected high-risk individuals) reduces
HIV/AIDS prevalence from 29% to 18.7% in 50 years. ART to
treat 75% of all new infections would reduce disease prevalence to
a level between a 30% and 50% protective vaccine. A striking
short-term impact of TIP intervention on HIV incidence, as
compared to vaccines and ART, is also projected (Figure 2b)
despite extremely rapid rollout of vaccines and ART (Figure S1 in
Text S1). Similar results are obtained when comparing TIP
intervention to vaccination and ART in terms of either the
fraction-of-individuals-living-with-AIDS or AIDS incidence (Fig-
ure S2 in Text S1). Thus, TIPs constructed using parameters
recently reported in Phase-I trials [17], and given to a small
fraction of the population (1%), have the potential to swiftly and
substantially reduce disease burden at the population level.
This efficacy and robustness of TIP intervention arises from the
unique and defining ability of TIPs to transmit between hosts.
Analysis of TIPs that generate a 0.5–1.5 Log decrease in viral load,
but do not transmit between hosts, shows only a minimal decrease
in population-level disease burden (Figure S3 in Text S1)—in
agreement with the projected impact of acyclovir treatment which
also generates a ,0.5 Log decrease in HIV viral load [33].
Accordingly, we have paid particular attention to ensuring that
our results are robust with respect to changes in basic model
assumptions about transmission biology and robust under
parameter sensitivity analysis (see Text S1). We also consider
two competing models of HIV transmission biology—infection by
either a single ‘founder’ virus that enters the new host individual or
‘bottlenecking’ where multiple viruses enter and replicate locally
but are then winnowed down by competition within the host
[35,36,37]—and we provide arguments that our treatment of TIP
transmission is consistent with either transmission mode and that
TIPs could transmit efficiently in either case (see Text S1 section
Figure 1. Therapeutic Interfering Particle (TIP) intervention modeled at multiple scales. (Upper right box) Schematic of the sub-cellular
level model where TIP genomes (blue) mobilize by ‘stealing’ packaging elements from the wild-type virus (red, e.g. HIV) within a dually infected cell
[22]. (Lower right box) Schematic of the in vivo model where TIP (blue) is produced from dually infected cells and reduces wild-type HIV viral set-point
[19] within a dually infected individual. (Left box) Schematic of the population model where TIP and HIV transmit between individuals of different
sexual activity classes (based on UNAIDS Malawi antenatal clinic data [12]). Boldness of figures represents transmission rate, size of figures represents
size of sexual activity class. Smallest but boldest figures represent the superspreaders (the least in number but the highest transmission rate). Largest
but lightest figures represent individuals with the lowest transmission rates (the greatest in number). Infection by TIP alone (blue) converts
susceptible individuals to into latent ‘carriers’ of integrated TIP genomes [22]. Infection by HIV converts susceptible individuals to individuals who
progress to disease in ,10 yrs. Dual infection generates individuals who progress to disease more slowly. Disease progression and transmission rates
are proportional to in vivo viral loads [25].
doi:10.1371/journal.pcbi.1002015.g001
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completely sure that our model results are robust to changes in
assumptions about TIP transmission, we repeated the simulations
under the worst-case assumption that TIPs are completely unable
to transmit in the absence of HIV, and found results that are
qualitatively unchanged from Figure 2 (see Text S1 section:
‘‘Sensitivity of model to removal of independent transmission of TIPs (i.e.
removal of ST individuals)’’). This somewhat surprising result arises
because TIPs autonomously target the highest-risk groups, which
are highly likely to be already infected with HIV due to their high-
risk status, and thus the majority of the TIP infection ‘flow’ occurs
through the already infected individuals. In summary, while there
is physiological basis to support that TIPs could transmit efficiently
to HIV-uninfected persons, the efficacy of TIP intervention is
largely independent of this assumption (i.e. TIPs need not convert
susceptible individuals into ‘TIP carriers’ for population-level
efficacy to be retained).
These results are not intended to argue that ART campaigns be
abandoned or vaccine trials be halted. On the contrary, as we
show below, the TIP’s ability to target high-risk groups allows the
TIP to complement ART (or vaccine) campaigns and significantly
enhance the population-level efficacy of these approaches.
TIPs would circumvent behavioral barriers and
complement pharmaceutical treatment
Current prevention and treatment approaches also face the
challenges of poor compliance and behavioral disinhibition,
wherein successful disease control leads to a reduced sense of
personal risk from the disease and can result in increases in risk
behavior. Disinhibition is a significant concern for current HIV
prevention and control [38] and has the potential to generate the
perverse outcome that a successful therapeutic may actually
increase HIV incidence [39]. The transmissibility and single-dose
administration of TIPs effectively circumvent these problems,
unlike current pharmaceutical approaches (i.e. ART) or vaccina-
tion. Indeed, the public health benefits of TIPs are uniquely robust
to disinhibition, since the intervention spreads more effectively if
contact rates increase (Figure 3a). In contrast, the same degree of
disinhibition in the presence of ART or a 30% or 50% protective
Figure 2. TIPs out-perform optimistic HIV vaccines and antiretroviral therapy (ART). Projected impact of TIP intervention on (a) HIV/AIDS
disease prevalence over 50 years (b) and HIV incidence per 100,000 individuals over 30 years, for two scenarios of TIP efficacy: a 0.5-Log viral-load
reduction (upper blue line) and a 1.5-Log viral load reduction (lower blue line), based on a recent clinical trial [17], both initially deployed to 1% of
individuals. TIP intervention is compared to a 30% protective vaccine (light grey), a 50% protective vaccine (dark grey), and ART (black). Vaccine
scenarios are based on protection levels reported in a recent clinical trial [34] and UNAIDS target protection goals (50% protection) where each
vaccine is assumed to have lifelong efficacy and optimistic levels of coverage (80% and 95% coverage of all risk groups, respectively). The ART
scenario is assumed to treat 75% of all infections using a universal test-and-treat approach [27] where ART has 99% efficacy in halting HIV
transmission.
doi:10.1371/journal.pcbi.1002015.g002
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prevalence and could increase the number of deaths due to AIDS
(Figure 3b), as highlighted by previous analyses [39].
Any intervention against HIV is likely to be administered in the
context of the existing ‘standard of care’: ART. Since ART halts
HIV transmission, ART would also halt TIP transmission from an
individual, leading to the potential that the TIP intervention could
be severely hampered. However, the TIP’s ability to concentrate
in highest-risk groups (see next paragraph), where ART is at best
the target coverage fraction (e.g. 75%), would allow TIP
Figure 3. TIPs are resistant to behavioral disinhibition and would complement pharmaceutical approaches to reduce HIV/AIDS
disease prevalence. Projected 50-year impact of TIP intervention on (a) HIV/AIDS disease prevalence and (b) number of deaths averted in the
presence and absence of behavioral disinhibition (dashed and solid lines, respectively). TIP interventions (light and dark blue) are compared to
vaccination (light and dark grey), ART (black), and the scenario of no intervention (dashed red line). Disinhibition is modeled as in [39] by assuming
that individual person-to-person contact rates increase upon introduction of vaccine or TIP intervention. Projected 50-year impact of ART in presence
of TIP intervention (light and dark purple)o n( c) HIV/AIDS disease prevalence and (d) number of deaths averted compared to projected 50-year impact
of ART alone (black, 75% ART coverage without TIP intervention). Dashed and solid lines are the presence and absence of behavioral disinhibition,
respectively. ART and vaccine campaigns are modeled as in Figure 2.
doi:10.1371/journal.pcbi.1002015.g003
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prevalence, and reduce AIDS deaths, more effectively than ART
alone, even under optimistic coverage scenarios for ART
campaigns (Figure 3c–d). Thus, ART would not interfere with
TIP intervention at the population scale, and TIPs could be used
as a powerful complement to ART and pharmaceutical treatments
in general.
TIPs would autonomously target high-risk groups
The increased efficacy of TIPs relative to vaccination is due to
the TIP’s transmissibility along the same transmission routes as the
pathogen. Consequently, the TIP transmits to a specific risk group
in proportion to that group’s risk behavior, leading to more
focused targeting of TIPs in more heterogeneous populations and
resulting in TIPs concentrating in the highest-risk populations
(Figure 4a). In contrast, reaching high-risk classes with ART
depends upon active and sustained targeting of these rare high-risk
individuals, while partially-protective vaccines tend to concentrate
in the lowest risk classes (because higher-risk individuals still
become HIV-infected, given partially protective vaccines) and lack
the ability to dynamically redistribute between risk classes
(Figure 4b).
Evolutionary considerations
Vaccines and drug treatment strategies also face the challenge of
mutation and the strong selective pressure for the pathogen to
escape any successful control. For HIV, rapid mutation leads to
resistance against anti-retroviral therapy and poses significant
challenges for vaccine development [40]. However, unlike
conventional therapies, TIPs replicate with the same speed and
mutation rate as the pathogen, which sets up an evolutionary arms
race between the TIP and the pathogen.
To examine how HIV might respond in such an arms race
resulting from TIP intervention, we consider the multi-scale
dynamics across a range of parameter values for the molecular-
level properties used to design a TIP. Specifically, we consider the
interplay of HIV and TIP levels as a function of both the strength
of TIP-encoded inhibition of HIV and the engineered TIP
genomic abundance within a dually infected cell. For HIV, the
TIP design encodes an inherent evolutionary tradeoff that
generates conflicting selection pressures at different scales
(Figure 5). On the one hand, inhibition of HIV replication by
TIP-encoded therapy genes inevitably limits TIP production—
since any TIP-encoded antiviral that inhibits HIV will compro-
mise the TIP’s ability to mobilize. However, due to the diploid
nature of retroviral genomes, high concentrations of TIP genomic
mRNA alone will inhibit HIV production by wasting the majority
of HIV genomes in virions containing one HIV RNA and one TIP
RNA, and these heterozygous-diploid virions are not viable
[18,23]. Thus, the lowest TIP-mediated inhibition generates the
highest production of TIPs from an infected cell (Figure 5a). The
increased numbers of TIP virions then compete more effectively
against HIV for target cells which generates a greater reduction in
HIV viral-load at the patient-level (Figure 5b), and the lowest
HIV/AIDS prevalence in the population (Figure 5c). These results
suggest a non-intuitive design criterion for a TIP against HIV:
TIPs lacking an inhibitory factor for HIV will be most effective in
reducing HIV levels, both in individual patients and at the
population level. Similarly, the cellular-scale selective pressure for
HIV to escape from TIP-encoded inhibition would point in the
same direction (toward zero TIP inhibitory effect) and would lead
to increased TIP production (Figure 5a). So, counter-intuitively,
HIV escape from TIP-mediated inhibition (at the molecular scale
within cells) would reduce HIV viral load and HIV population
prevalence to lower levels (Figure 5b–c).
Safety and ethical considerations
The TIP approach carries unique safety concerns [41] and
ethical concerns associated with introducing an intervention that
transmits and evolves, even in the TIP’s limited fashion, within the
population. Importantly, clear ethical precedents for transmissible
therapies exist in the use of live-attenuated vaccines. Regarding
safety, one major concern is that the TIP may recombine with (i.e.
acquire) an element that ‘upregulates’ pathogen production and in
turn upregulates its own production from the cell. To explore this
concern, we examine HIV viral load and population prevalence in
the regime where TIP encodes HIV inhibition and in the regime
where TIP encodes potential upregulation of HIV gene expression
within a single cell. (Figure 6a). As expected, at the single-cell level
upregulation of HIV generates increased HIV and TIP produc-
tion. However, at the individual patient level upregulation of HIV
leads to increased TIP viral loads (Figure 6a, inset) which actually
generate even lower HIV viral loads (Figure 6a) and HIV
population prevalence (Figure 6b). Interestingly, at the population
level, there is an optimal value of TIP-encoded inhibition, which
yields a maximum in TIP prevalence (Figure 6b, inset). Thus, the
TIP appears to be subject to competing selection pressures at
multiple scales which may limit the potential for evolutionary
breakdown of TIP therapies, echoing recent proposals for
antivirals that resist viral escape [42] and ‘evolution-proof’ malaria
insecticides [43].
Detailed experimental and theoretical study is required to
predict the ultimate direction of TIP evolution, but the competing
selection pressures may effectively constrain TIP phenotypes to a
range that assures low HIV viral load and low HIV disease
prevalence. TIP evolution is likely to be dominated by mutational
processes, since recombination between TIPs and wild-type HIV
appears to be severely limited by fundamental sequence-homology
constraints on retroviral recombination [44] that render recom-
bination between full-length 9.7 kb HIV genomes and shorter
lentiviral genomes (e.g. TIP) non-competent for integration [18].
This molecular argument against recombination between HIV
and TIP is also supported by data from murine models [45,46]
and the recent human clinical trial data [17], neither of which
detected recombination between wild-type HIV-1 and shorter
lentiviral therapy vectors.
To fully address safety, there is obviously a need for cautious
trials in vitro, and in vivo, before a TIP intervention could ever be
considered for implementation. Importantly, TIPs for HIV would
not specifically target, or require, stem cells since the TIP would
target the same cells as HIV (primarily CD4
+ T lymphocytes) and
thus oncogenic concerns as a result of insertional mutagenesis [47]
are minimized. This argument is supported by a recent Phase-I
lentiviral gene-therapy clinical trial for HIV [17] and previous
gene therapy in peripheral blood lymphocytes in patients followed
since 1995 [48], neither of which detected insertional mutagenesis
or oncogenic transformation in patients.
Conclusion and the way forward
As with all models, our analysis is a relatively simple
representation of a complex system and necessarily makes certain
assumptions. Importantly, the TIP’s robustness and efficacy stems
from the unique and defining ability of TIPs to transmit between
hosts and, as such, the general results presented for the TIP are
qualitatively robust to changes in parameter values or in basic
model assumptions about transmission biology (see Text S1). TIP
efficacy also appears qualitatively robust to decreases in transmis-
Halting HIV Spread with Engineered TIPs
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d) or re-parameterization of transmission functions (see Text S1).
Nevertheless, our analysis is intended as a first step towards
motivating research into transmissible therapies, rather than a
proof of efficacy. The molecular, epidemiological, and ethical
bases of using TIP intervention against pathogens will require
extensive study, but our results show that TIPs may offer a unique
strategy for targeting both high-risk and hard-to-reach popula-
tions, overcoming behavioral barriers, and circumventing muta-
tional escape to achieve indefinite disease suppression of HIV, and
possibly other pathogens, in resource-limited settings.
As an added benefit for intervention in resource-limited
settings, TIPs may have the potential to be administered as a
therapy requiring only a single dose, thereby allowing for
Figure 4. TIPs autonomously target superspreaders. (a) Ability of TIP intervention to penetrate each risk-class as reported by fraction of each
risk-class exposed to intervention over time. Despite introduction into far more individuals in the lowest risk class (due to our assumption of uniform
1% initial coverage), TIPs can mobilize into the highest risk superspreader class. Solid and dashed lines represent simulations in the presence of
behavioral disinhibition, respectively. (b) Ability of 50% protective vaccine, administered to 95% of the population, to penetrate each risk-class as
reported by fraction of each risk-class exposed to vaccination over time. Solid and dashed lines represent simulations in the presence of behavioral
disinhibition, respectively. In contrast to TIPs, a 50% protective vaccine that is directly targeted to the highest risk class is quickly depleted from the
highest risk-class because, given partial protection, high-risk individuals still become infected relatively rapidly.
doi:10.1371/journal.pcbi.1002015.g004
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ance issues. Our results shows that deploying TIPs as a therapy
to even a few individuals who are already infected can reduce
t h ep r e v a l e n c eo fad i s e a s et ov e r yl o wl e v e l s .D u et ot h er a p i d
and sustained transmission dynamics in high-risk groups, the
impact of TIP intervention is robust even if the TIP is quickly
cleared from TIP ‘carriers’ so that these individuals rapidly
revert back to ‘susceptibles’ (see Text S1). With the ability to
Figure 5. TIP intervention is robust to the evolution of pathogen resistance. Projected steady-state values for: (a) HIV and TIP production
from dually infected cells at the single-cell level; (b) HIV and TIP viral loads at the individual patient level in vivo; and (c) HIV/AIDS prevalence at the
population level. At each scale, values are plotted as a function of two molecular-level design criteria: (i) the expression-level of TIP genomic mRNA
over HIV genomic mRNA (parameter P from the intracellular model, see Text S1), and (ii) TIP-encoded inhibition of HIV gene expression (parameter D
from the intracellular model, see Text S1) where 1.0 corresponds to complete inhibition of HIV, 0.0 corresponds to no inhibition of HIV (when D=0.0,
HIV viral load is reduced only by ‘wasting’ of HIV genomes in nonviable heterozygous virions). TIPs lacking active inhibition of HIV display higher
production at the single-cell level and, counter-intuitively, inhibit HIV more potently at the individual patient level and at the population level by
outcompeting HIV for targets. Purple ‘HIV escape’ arrows represent the direction of HIV evolution to evade direct inhibition by TIP-encoded
molecules.
doi:10.1371/journal.pcbi.1002015.g005
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to ART on an individual scale, by reactivating during ART
failure and acting to reduce viral load. While recent models
argue that widespread ART campaigns alone could halt the
HIV/AIDS pandemic [27,28], there remains significant con-
troversy as to whether ART can succeed in reducing overall
HIV transmission [12,29], especially in the presence of high-risk
groups exhibiting treatment non-compliance. Significant chal-
lenges to achieving widespread ART coverage in resource-
limited settings include: slower-than-hoped rollout, persistent
logistical problems linked to insufficient health systems and
weak infrastructure, the need for on-going high-level donor
funding, and the social stigmas that prevent people from getting
tested and hence starting treatment. These factors will likely
produce long-term heterogeneity in coverage, with the most
impoverished and disadvantaged groups receiving the least
access to ART. Based on these challenges, it is prudent to
consider alternative and complementary approaches.
Materials and Methods
The multi-scale analysis of TIPs and HIV-1 is built upon
previous data-driven models [12,19] and is composed of three
constituent ordinary differential equation models describing
dynamics at different hierarchical scales: (i) among a population
of host individuals (‘population level’) (ii) within host individuals
(‘individual patient’) (iii) within infected host cells (‘intracellular’).
The multi-scale model specifies mechanistic links between each
scale and the next scale of organizational complexity (intracellular
R in vivo R population level).
Figure 6. TIPs evolve toward robust reduction in disease prevalence. (a) Predicted HIV viral set point as a function of TIP encoded inhibition
of HIV (parameter D from the intracellular model, see Text S1) where negative inhibition values indicate TIP evolving to upregulate HIV gene
expression within a single cell. Inset: Increasing upregulation generates higher TIP viral loads at the individual patient level and leads to lower HIV
viral loads. (b) HIV/AIDS disease prevalence as a function of TIP encoded inhibition of HIV where negative inhibition values indicate TIP evolving to
upregulate HIV expression. Increasing upregulation generates lower HIV/AIDS prevalence at the population level. Inset: TIP prevalence is reduced as
upregulation increases, potentially creating an evolutionary trap for the TIP.
doi:10.1371/journal.pcbi.1002015.g006
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structured model constructed from UNAIDS field-data collected
from antenatal clinics in Malawi [12], which includes a risk-
structure formulation with four distinct sexual-activity classes
(SACs) and which we refer to as the ‘Baggaley model’. Individuals
are classified as susceptible (S), HIV infected (I), susceptible to HIV
but infected with TIP (St), dually infected with HIV and TIP (Id), as
an AIDS patient with wild-type virus (Aw), or as a dually infected
AIDS patient (Ad). Individuals in all disease-states are divided into
SACs in accordance with field data (indicated by subscript i),
except that all individuals in the Aw class are assumed (as in [12]) to
have sexual contacts at the rate corresponding to the lowest risk
group (SAC 4) owing to their poor health. The model equations
are as follows:
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Parameter definitions, values, and corresponding references are
shown in Table S1 in Text S1. The transmission probabilities per
partnership are denoted b
Y
X where Y represents the disease state of
the source of the infection, and X represents the viral strain (which
is wild-type HIV, denoted X=W, for the vaccine model). The per-
partnership transmission probability b
I
W (describing transmission
of wild-type HIV by individuals in the I disease state) is set to agree
with the weighted average of the Baggaley model [12] and b
A
W is
the per-partnership probability of wild-type HIV infection
originating from an AIDS patient, and is set following the
Baggaley model [12]. Consideration of alternative parameteriza-
tions of the viral load transmission curve did not qualitatively affect
the results (see Text S1). The parameters b
I
W and c1 are static
parameters that represent the transmission probability and the
duration of the asymptomatic phase of individuals infected with
only wild-type virus. In contrast, to describe quantities that depend
on the specific design of the TIP, such as: (i) transmission
probabilities, and (ii) the duration of the asymptomatic period,
functions are used in place of parameters. These functions are
calculated based on measured correlations between transmission,
disease progression, and viral load [25,26] where viral load is
predicted from the in vivo TIP model (see Text S1). For example,
the transmission probabilities in the presence of TIP and the
duration of the asymptomatic phase in dually-infected individuals
in the TIP population models are represented by functions of
steady-state viral load (i.e. viral set point) as predicted by the in vivo
model (see Table S3 in Text S1 for a description of the
transmission-probability functions). The function c2 V ðÞ is used
to compute the duration of the asymptomatic phase in dually-
infected individuals, and is also calculated in Text S1.
Contacts between individuals in the TIP population model are
weighted by statistically independent transmission probabilities (b)
which are calculated from steady-state HIV and TIP viral loads
from the in vivo model (see Text S1 section: ‘Calculation of
Transmission-Rate Function’). There are six distinct transitions
between infection classes in the TIP population model (see Table
S3 in Text S1 for details). Briefly, contact between two individuals
is represented by a contact function that considers asymmetric
mixing of individuals among the four SACs:
CX i,Y ðÞ ~ciXi e
Yi
Ni
  
z 1{e ðÞ
P 4
j~1
cjYj
P 4
j~1
cjNj
2
6 6 6 4
3
7 7 7 5
This contact function describes an individual in disease state X
(and SAC i) becoming infected by an individual in disease state Y.
The subscript j denotes SAC j, cj is the average number of sexual
partners per year in SAC j, and Nj is the sum of all sexually active
individuals in SAC j. In the contact function, e is the degree of
assortative mixing with e~1 corresponding to entirely assortative
mixing and e~0 corresponding to entirely random mixing. The
first term inside the brackets of the contact function describes
assortative mixing in which infected individuals are encountered in
proportion to their prevalence in SAC i. The second term
describes random contacts in which infected individuals are
encountered in proportion to their contribution to all of the sexual
contacts being made in the entire population. We set the mixing
parameter e equal to 0.37, as estimated in [12].
Simulation of the TIP population model is conducted as follows:
the Baggaley model is allowed to reach steady-state and then a
TIP is introduced to 1% of all individuals without any targeting to
high-risk classes. Similar benefits were obtained using much more
restrictive initial conditions (e.g. utilizing TIP as a therapy and
targeting TIP to ,1% of only I and Aw individuals in the least
active SACs—SAC 3 and SAC 4—generates similar results to
Halting HIV Spread with Engineered TIPs
PLoS Computational Biology | www.ploscompbiol.org 10 March 2011 | Volume 7 | Issue 3 | e1002015Figure 2). Behavioral disinhibition is simulated as in [49] by
increasing the contact rates c for all SACs and number of AIDS
deaths averted by the vaccination campaign is defined as:
AIDS deaths averted = (AIDS deaths during 100 years of
epidemic without treatment) – (AIDS deaths during a 50 year
epidemic followed by 50 years of treatment).
Vaccine and ART models use the same risk structure as above
and are presented in Text S1. A complete list of model parameters
and state variables are presented in Tables S1, S2, S3, S4, S5, S6,
and S7 in Text S1.
All numerical simulations were performed in Mathematica 7.0.
Supporting Information
Text S1 Full description of the multi-scale model used to predict
the effects of a TIP intervention on HIV-1 infection dynamics
among a population of host individuals, within host individuals,
and within host cells. This report contains detailed descriptions of
each model, tables of parameters and state variables, supporting
figures, an analysis of the sensitivity of the TIP model to changes in
parameters, and an analysis of the sensitivity of the TIP model to
changes in structure and changes in basic transmission biology.
(PDF)
Acknowledgments
We are grateful to John J. Holland, Douglas Richman, Davey Smith, Alan
Perelson, Ariel Weinberger, Ruian Ke, Travis Porco, John Mittler and
Matt Strain for helpful comments, and to Harish Nagarajan for technical
assistance. This manuscript is dedicated to our late friend and colleague
Eran Karmon who helped initiate this work with engaging discussions and
enthusiasm.
Author Contributions
Conceived and designed the experiments: LSW. Performed the experi-
ments: LSW. Analyzed the data: VTM JOLS LSW. Contributed reagents/
materials/analysis tools: LSW. Wrote the manuscript: VTM JOLS LSW.
References
1. Hethcote HW, Yorke JA (1984) Gonorrhea transmission dynamics and control.
Berlin; New York: Springer-Verlag. ix. 105 p.
2. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and
control. Oxford; New York: Oxford University Press. viii. 757 p.
3. Woolhouse ME, Dye C, Etard JF, Smith T, Charlwood JD, et al. (1997)
Heterogeneities in the transmission of infectious agents: implications for the
design of control programs. Proc Natl Acad Sci U S A 94: 338–342.
4. Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM (2005) Superspreading and
the effect of individual variation on disease emergence. Nature 438: 355–359.
5. Pareto V (1971) Manual of political economy. New York: A. M. Kelley. xii.
504 p.
6. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, et al. (2009) Evidence
of a large, international network of HCV transmission in HIV-positive men who
have sex with men. Gastroenterology 136: 1609–1617.
7. Grassly NC, Fraser C, Garnett GP (2005) Host immunity and synchronized
epidemics of syphilis across the United States. Nature 433: 417–421.
8. Woodhouse DE, Rothenberg RB, Potterat JJ, Darrow WW, Muth SQ, et al.
(1994) Mapping a social network of heterosexuals at high risk for HIV infection.
AIDS 8: 1331–1336.
9. May RM, Anderson RM (1987) Transmission dynamics of HIV infection.
Nature 326: 137–142.
10. Woolhouse ME (1998) Patterns in parasite epidemiology: the peak shift. Parasitol
Today 14: 428–434.
11. Sars Investigation Team from DMERI (2005) Strategies adopted and lessons
learnt during the severe acute respiratory syndrome crisis in Singapore. Rev
Med Virol 15: 57–70.
12. Baggaley RF, Garnett GP, Ferguson NM (2006) Modelling the impact of
antiretroviral use in resource-poor settings. PLoS Med 3: e124.
13. Kahn JG (1996) The cost-effectiveness of HIV prevention targeting: how much
more bang for the buck? Am J Public Health 86: 1709–1712.
14. Cowan FM, Hargrove JW, Langhaug LF, Jaffar S, Mhuriyengwe L, et al. (2005)
The appropriateness of core group interventions using presumptive periodic
treatment among rural Zimbabwean women who exchange sex for gifts or
money. J Acquir Immune Defic Syndr 38: 202–207.
15. Holland JJ (1990) Generation and replication of defective viral genomes. In:
Fields BN, Knipe DM, eds. Fields Virology. 2nd ed.. New York: Raven Press. pp
77–99.
16. Klimatcheva E, Planelles V, Day SL, Fulreader F, Renda MJ, et al. (2001)
Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its
replication. Mol Ther 3: 928–939.
17. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006)
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc
Natl Acad Sci U S A 103: 17372–17377.
18. An DS, Morizono K, Li QX, Mao SH, Lu S, et al. (1999) An inducible human
immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-
1 replication. J Virol 73: 7671–7677.
19. Weinberger LS, Schaffer DV, Arkin AP (2003) Theoretical design of a gene
therapy to prevent AIDS but not human immunodeficiency virus type 1
infection. J Virol 77: 10028–10036.
20. Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC (2006) Long-term
transmission of defective RNA viruses in humans and Aedes mosquitoes. Science
311: 236–238.
21. Fine PE, Carneiro IA (1999) Transmissibility and persistence of oral polio
vaccine viruses: implications for the global poliomyelitis eradication initiative.
Am J Epidemiol 150: 1001–1021.
22. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV (2005)
Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat
fluctuations drive phenotypic diversity. Cell 122: 169–182.
23. Chen J, Nikolaitchik O, Singh J, Wright A, Bencsics CE, et al. (2009) High
efficiency of HIV-1 genomic RNA packaging and heterozygote formation
revealed by single virion analysis. Proc Natl Acad Sci U S A 106: 13535–
13540.
24. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1
dynamics in vivo: virion clearance rate, infected cell life-span, and viral
generation time. Science 271: 1582–1586.
25. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP (2007)
Variation in HIV-1 set-point viral load: epidemiological analysis and an
evolutionary hypothesis. Proc Natl Acad Sci U S A 104: 17441–17446.
26. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, et al. (1996)
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
Science 272: 1167–1170.
27. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal
voluntary HIV testing with immediate antiretroviral therapy as a strategy for
elimination of HIV transmission: a mathematical model. Lancet 373: 48–57.
28. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, et al. (2006) The case for
expanding access to highly active antiretroviral therapy to curb the growth of the
HIV epidemic. Lancet 368: 531–536.
29. Garnett GP, Baggaley RF (2009) Treating our way out of the HIV pandemic:
could we, would we, should we? Lancet 373: 9–11.
30. Fox MP, Rosen S (2010) Patient retention in antiretroviral therapy programs up
to three years on treatment in sub-Saharan Africa, 2007-2009: systematic
review. Trop Med Int Health 15 Suppl 1: 1–15.
31. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy
programs in sub-Saharan Africa: a systematic review. PLoS Med 4: e298.
32. Rosen S, Sanne I, Collier A, Simon JL (2005) Rationing antiretroviral therapy
for HIV/AIDS in Africa: choices and consequences. PLoS Med 2: e303.
33. Baggaley RF, Griffin JT, Chapman R, Hollingsworth TD, Nagot N, et al. (2009)
Estimating the public health impact of the effect of herpes simplex virus
suppressive therapy on plasma HIV-1 viral load. AIDS 23: 1005–1013.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al.
(2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in
Thailand. N Engl J Med 361: 2209–2220.
35. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008)
Identification and characterization of transmitted and early founder virus
envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105:
7552–7557.
36. Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, et al.
(2009) Inflammatory genital infections mitigate a severe genetic bottleneck in
heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 5:
e1000274.
37. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, et al. (2002) Virus population
homogenization following acute human immunodeficiency virus type 1
infection. J Virol 76: 11953–11959.
38. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, et al. (2001) Sexual
risk behaviour relates to the virological and immunological improvements during
highly active antiretroviral therapy in HIV-1 infection. AIDS 15: 369–378.
39. Blower SM, Gershengorn HB, Grant RM (2000) A tale of two futures: HIV and
antiretroviral therapy in San Francisco. Science 287: 650–654.
40. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature
455: 613–619.
Halting HIV Spread with Engineered TIPs
PLoS Computational Biology | www.ploscompbiol.org 11 March 2011 | Volume 7 | Issue 3 | e100201541. Kirkwood TB, Bangham CR (1994) Cycles, chaos, and evolution in virus
cultures: a model of defective interfering particles. Proc Natl Acad Sci U S A 91:
8685–8689.
42. Endy D, Yin J (2000) Toward antiviral strategies that resist viral escape.
Antimicrob Agents Chemother 44: 1097–1099.
43. Read AF, Lynch PA, Thomas MB (2009) How to make evolution-proof
insecticides for malaria control. PLoS Biol 7: e1000058.
44. Temin HM (1993) Retrovirus variation and reverse transcription: abnormal
strand transfers result in retrovirus genetic variation. Proc Natl Acad Sci U S A
90: 6900–6903.
45. Davis BM, Humeau L, Dropulic B (2004) In vivo selection for human and
murine hematopoietic cells transduced with a therapeutic MGMT lentiviral
vector that inhibits HIV replication. Mol Ther 9: 160–172.
46. Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, et al. (2010)
HIV Sequence Variation Associated With env Antisense Adoptive T-cell
Therapy in the hNSG Mouse Model. Mol Ther 18: 803–811.
47. Pike-Overzet K, van der Burg M, Wagemaker G, van Dongen JJ, Staal FJ (2007)
New insights and unresolved issues regarding insertional mutagenesis in X-
linked SCID gene therapy. Mol Ther 15: 1910–1916.
48. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, et al. (1995)
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-
immunodeficient patients. Science 270: 470–475.
49. Blower SM, McLean AR (1994) Prophylactic vaccines, risk behavior change,
and the probability of eradicating HIV in San Francisco. Science 265:
1451–1454.
Halting HIV Spread with Engineered TIPs
PLoS Computational Biology | www.ploscompbiol.org 12 March 2011 | Volume 7 | Issue 3 | e1002015